[{"Assets_0_Q2_USD":491144000.0,"CommonStockSharesOutstanding_0_Q2_shares":40370521.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-17494000.0,"NetIncomeLoss_1_Q2_USD":-22329000.0,"NetIncomeLoss_2_Q2_USD":-40707000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":41337000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":79769000.0,"StockholdersEquity_0_Q2_USD":287989000.0,"Ticker":"TVTX","CIK":"1438533","name":"RETROPHIN, INC.","OfficialName":"Travere Therapeutics Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1905907401.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180803"}]